Allakos (ALLK) will discontinue further development of AK006

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to Allakos (ALLK) will discontinue further development of AK006

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

January 27, 2025 7:00 AM EST

 AK006 did not demonstrate therapeutic activity in CSU
Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives
Management to host conference call and webcast today at 8:30 am E.T. 

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has... More